Bio-Rad Laboratories Inc (BIO) - Total Assets
Based on the latest financial reports, Bio-Rad Laboratories Inc (BIO) holds total assets worth $10.58 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BIO total equity for net asset value and shareholders' equity analysis.
Bio-Rad Laboratories Inc - Total Assets Trend (1985–2025)
This chart illustrates how Bio-Rad Laboratories Inc's total assets have evolved over time, based on quarterly financial data.
Bio-Rad Laboratories Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Bio-Rad Laboratories Inc's total assets of $10.58 Billion consist of 27.5% current assets and 72.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $529.80 Million | 5.0% |
| Accounts Receivable | $472.50 Million | 4.5% |
| Inventory | $740.70 Million | 7.0% |
| Property, Plant & Equipment | $709.90 Million | 6.7% |
| Intangible Assets | $174.30 Million | 1.7% |
| Goodwill | $579.80 Million | 5.5% |
Asset Composition Trend (1985–2025)
This chart illustrates how Bio-Rad Laboratories Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIO market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Rad Laboratories Inc's current assets represent 27.5% of total assets in 2025, a decrease from 75.4% in 1985.
- Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, down from 8.4% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is inventory at 7.0% of total assets.
Bio-Rad Laboratories Inc Competitors by Total Assets
Key competitors of Bio-Rad Laboratories Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Bio-Rad Laboratories Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.62 | 6.48 | 3.57 |
| Quick Ratio | 4.19 | 4.85 | 2.57 |
| Cash Ratio | 1.02 | 1.04 | 0.00 |
| Working Capital | $2.39 Billion | $2.56 Billion | $1.57 Billion |
Bio-Rad Laboratories Inc - Advanced Valuation Insights
This section examines the relationship between Bio-Rad Laboratories Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.95 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | 12.9% |
| Total Assets | $10.58 Billion |
| Market Capitalization | $5.62 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bio-Rad Laboratories Inc's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bio-Rad Laboratories Inc's assets grew by 12.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bio-Rad Laboratories Inc (1985–2025)
The table below shows the annual total assets of Bio-Rad Laboratories Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.58 Billion | +12.95% |
| 2024-12-31 | $9.36 Billion | -23.86% |
| 2023-12-31 | $12.30 Billion | -8.91% |
| 2022-12-31 | $13.50 Billion | -24.15% |
| 2021-12-31 | $17.80 Billion | +37.21% |
| 2020-12-31 | $12.97 Billion | +61.98% |
| 2019-12-31 | $8.01 Billion | +42.73% |
| 2018-12-31 | $5.61 Billion | +31.31% |
| 2017-12-31 | $4.27 Billion | +10.97% |
| 2016-12-31 | $3.85 Billion | +3.80% |
| 2015-12-31 | $3.71 Billion | +11.03% |
| 2014-12-31 | $3.34 Billion | -1.40% |
| 2013-12-31 | $3.39 Billion | -1.59% |
| 2012-12-31 | $3.44 Billion | +11.20% |
| 2011-12-31 | $3.10 Billion | +1.11% |
| 2010-12-31 | $3.06 Billion | +20.78% |
| 2009-12-31 | $2.54 Billion | +24.47% |
| 2008-12-31 | $2.04 Billion | +3.33% |
| 2007-12-31 | $1.97 Billion | +23.52% |
| 2006-12-31 | $1.60 Billion | +11.89% |
| 2005-12-31 | $1.43 Billion | +4.01% |
| 2004-12-31 | $1.37 Billion | +38.18% |
| 2003-12-31 | $992.60 Million | +37.73% |
| 2002-12-31 | $720.70 Million | +5.36% |
| 2001-12-31 | $684.03 Million | +5.84% |
| 2000-12-31 | $646.28 Million | -3.38% |
| 1999-12-31 | $668.90 Million | +82.11% |
| 1998-12-31 | $367.30 Million | +4.38% |
| 1997-12-31 | $351.90 Million | +23.52% |
| 1996-12-31 | $284.90 Million | -0.07% |
| 1995-12-31 | $285.10 Million | +8.12% |
| 1994-12-31 | $263.70 Million | +1.46% |
| 1993-12-31 | $259.90 Million | -4.69% |
| 1992-12-31 | $272.70 Million | +7.74% |
| 1991-12-31 | $253.10 Million | +18.71% |
| 1990-12-31 | $213.20 Million | +15.62% |
| 1989-12-31 | $184.40 Million | +18.74% |
| 1988-12-31 | $155.30 Million | +17.65% |
| 1987-12-31 | $132.00 Million | +29.92% |
| 1986-12-31 | $101.60 Million | +42.10% |
| 1985-12-31 | $71.50 Million | -- |
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, pu… Read more